Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA5 | P11021 | 6/20 | 0.47 |
| ▸ | FDPS | P14324 | 1/20 | 0.46 |
| ▸ | HSPA9 | P38646 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.43 |
| ▸ | HSPA8 | P11142 | 1/20 | 0.43 |
| ▸ | HSPA2 | P54652 | 1/20 | 0.42 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10299127 | 0.84 | HSPA5 (0.49) | HSPA5FDPSHSPA9LMNATSHR | |
| SCHEMBL12966147 | 0.76 | HSPA9 (0.52) | HSPA5FDPSHSPA9LMNATSHR | |
| SCHEMBL4455601 | 0.76 | FDPS (0.46) | HSPA5FDPSLMNATSHRADORA2A | |
| SCHEMBL4455593 | 0.76 | FDPS (0.46) | HSPA5FDPSLMNATSHRADORA2A | |
| SCHEMBL4469605 | 0.76 | FDPS (0.46) | HSPA5FDPSLMNATSHRADORA2A | |
| SCHEMBL13124653 | 0.74 | KDM4E (0.38) | LMNAFFAR2MEN1KMT2ANPC1 | |
| SCHEMBL43587 | 0.72 | FDPS (0.53) | HSPA5FDPSHSPA9LMNATSHR | |
| SCHEMBL43586 | 0.72 | FDPS (0.53) | HSPA5FDPSHSPA9LMNATSHR | |
| SCHEMBL288965 | 0.72 | FDPS (0.53) | HSPA5FDPSHSPA9LMNATSHR | |
| SCHEMBL12884426 | 0.71 | LMNA (0.58) | HSPA5HSPA9LMNATSHRADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10039754-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20170157104-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-9278922-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20100267634-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267634-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | HSPA5 1232/4885FDPS 211/4885HSPA9 1176/4885 |
| US-20170157104-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | HSPA5 1232/4885FDPS 211/4885HSPA9 1176/4885 |
| US-10039754-B2 | Anti-viral compounds | HAVCR2, EIF2AK2, MAVS | HSPA5 1232/4885FDPS 211/4885HSPA9 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.